Cargando…
Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486137/ https://www.ncbi.nlm.nih.gov/pubmed/35278141 http://dx.doi.org/10.1007/s00701-022-05181-2 |
| _version_ | 1784792212484128768 |
|---|---|
| author | Wang, Qiang Niu, Wenhao Pan, Hao |
| author_facet | Wang, Qiang Niu, Wenhao Pan, Hao |
| author_sort | Wang, Qiang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9486137 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Vienna |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94861372022-09-21 Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report Wang, Qiang Niu, Wenhao Pan, Hao Acta Neurochir (Wien) Correction Springer Vienna 2022-03-12 2022 /pmc/articles/PMC9486137/ /pubmed/35278141 http://dx.doi.org/10.1007/s00701-022-05181-2 Text en © Springer-Verlag GmbH Austria, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Wang, Qiang Niu, Wenhao Pan, Hao Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title_full | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title_fullStr | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title_full_unstemmed | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title_short | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report |
| title_sort | correction to: targeted therapy with anlotinib for a h3k27m-mutant diffuse midline glioma patient with pdgfr‑α mutation: a case report |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486137/ https://www.ncbi.nlm.nih.gov/pubmed/35278141 http://dx.doi.org/10.1007/s00701-022-05181-2 |
| work_keys_str_mv | AT wangqiang correctiontotargetedtherapywithanlotinibforah3k27mmutantdiffusemidlinegliomapatientwithpdgframutationacasereport AT niuwenhao correctiontotargetedtherapywithanlotinibforah3k27mmutantdiffusemidlinegliomapatientwithpdgframutationacasereport AT panhao correctiontotargetedtherapywithanlotinibforah3k27mmutantdiffusemidlinegliomapatientwithpdgframutationacasereport |